MCM
IHE icon

Monument Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Monument Capital Management’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.02M Buy
+60,787
New +$5.48M 1.21% 17

Other funds holding IHE

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return
AWM
Accurate Wealth Management Wesley Chapel, Florida $1.05B AUM 30.92% 1-Year Est. Return
FP
FFG Partners Fort Lauderdale, Florida $352M AUM 70.53% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
AFG
Arkansas Financial Group Little Rock, Arkansas $768M AUM 16.55% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return
SIA
SeaBridge Investment Advisors Summit, New Jersey $692M AUM 52.26% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AIFAIM
American Institute for Advanced Investment Management Scottsdale, Arizona $173M AUM 25.3% 1-Year Est. Return

Monument Capital Management's IHE Position: Q2 2026 in Review

Monument Capital Management opened a new position in iShares US Pharmaceuticals ETF (IHE) in Q2 2026: 60,787 shares worth $6.02M. The stake represents 1.21% of the portfolio and ranks #17 among its holdings.

40 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

  • Monument Capital Management held 60,787 shares of iShares US Pharmaceuticals ETF worth $6.02M as of Q2 2026.
  • iShares US Pharmaceuticals ETF was a new Monument Capital Management position in Q2 2026.
  • iShares US Pharmaceuticals ETF made up 1.21% of Monument Capital Management's portfolio in Q2 2026, its #17 holding.
  • 40 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Monument Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.